Biotech | April 13, 2022
Zydus to supply Sagent's caffeine citrate oral solution from Jarod
This product is indicated for the short-term treatment of a breathing problem (apnea) in premature infants
This product is indicated for the short-term treatment of a breathing problem (apnea) in premature infants
The launch of medical cannabis products resulted from an agreement between the two companies signed in 2021
This drug-device combination product is a metered-dose inhaler (MDI), which contains both budesonide (a corticosteroid that reduces inflammation) and formoterol (a long-acting bronchodilator that relaxes muscles in the airways to improve breathing)
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
Restasis has been approved for use in the U.S. for nearly 20 years, but until today, there was no approved generic product of this drug
The stability is led by healthy demand in the domestic and emerging markets
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
Gland Pharma believes that they are amongst one of the first to file for this product and may be eligible for 180 days of generic drug exclusivity
Subscribe To Our Newsletter & Stay Updated
